Harm Outcomes Reported by Patients with Rheumatic and Musculoskeletal Diseases Applicable for Interventional Trials: Protocol for Developing a Core Outcome Measurement Instrument

Read full text Summarise with VIRAT
Authors: Dorthe Bang Berthelsen, Amylou Constance Dueck, Glen Stewart Hazlewood, Pam Richards, Susan J. Bartlett, Clifton O. Bingham, Marieke Voshaar, John P. A. Ioannidis, Peter Tugwell, Beverley Shea, Niti Goel, Ben Horgan
+15 more THASIA G. WOODWORTH, Elisabeth Ginnerup‐Nielsen, Chris Djurtoft, Tanja Schjødt Jørgensen, Daniel E Furst, Randall M. Stevens, Amye L. Leong, Stacey Grealis, Grace Wright, A. Abou‐Raya, Tobias Haugegaard Hørlück, Peter Brooks, Lee S. Simon, Caroline Flurey, Robin Christensen
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Patients’ own reports of side effects - complementary to clinicians’ reports - improve the understanding of the lived experience, efficacy, and outcomes of medical treatment. The Outcome Measures in Rheumatology (OMERACT) Safety Working Group will develop a patient-reported outcome measurement instrument to assess symptomatic treatment-related side effects for people with rheumatic and musculoskeletal diseases (RMDs) enrolled in clinical trials. To adopt the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) into RMDs, we will first identify, classify, and select potential additional items of previously identified side effects and add response options and recall time frame for these items. Next, we will focus on content validity with input from patients, and then we will develop and pilot test the instrument. Finally, we will assess the feasibility of the instrument. A modified RMD version of the PRO-CTCAE instrument for clinical trials may furnish researchers, clinicians, and patients with an efficient, reliable, and valid assessment tool. However, our instrument might require subsequent validation in larger, more diverse, real-life situations and against other standards than described in this protocol.

Fields of Study & Subjects

Rheumatoid Arthritis Research and Therapies Statistical Methods in Clinical Trials Pharmacovigilance and Adverse Drug Reactions

Publication details

Publication date
1 January 2026
Language
EN
Document type
Preprint